{"id":47699,"date":"2025-11-13T22:18:37","date_gmt":"2025-11-13T14:18:37","guid":{"rendered":"https:\/\/flcube.com\/?p=47699"},"modified":"2025-11-13T22:18:39","modified_gmt":"2025-11-13T14:18:39","slug":"humanwell-initiates-phase-2-trial-of-hw231019-tablets-for-post%e2%80%91abdominal-surgery-analgesia","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=47699","title":{"rendered":"Humanwell Initiates Phase\u202f2 Trial of HW231019 Tablets for Post\u2011Abdominal Surgery Analgesia"},"content":{"rendered":"\n<p><strong>Humanwell Healthcare (Group) Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/600079:SHA\">SHA: 600079<\/a>)<\/strong> announced that it has begun a Phase\u202f2 clinical trial of its novel acute\u2011pain therapy, <strong>HW231019 tablets<\/strong>, aimed at reducing post\u2011operative pain after abdominal surgery.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-trial-overview\">Trial Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase<\/strong><\/td><td>Phase\u202f2<\/td><\/tr><tr><td><strong>Condition<\/strong><\/td><td>Post\u2011operative acute pain \u2013 abdominal surgery<\/td><\/tr><tr><td><strong>Primary Aim<\/strong><\/td><td>Evaluate efficacy &amp; safety of HW231019<\/td><\/tr><tr><td><strong>Secondary Aim<\/strong><\/td><td>Optimize dosing regimen for post\u2011operative analgesia<\/td><\/tr><tr><td><strong>Recruitment Goal<\/strong><\/td><td>200\u2011250 patients across 10 hospitals in China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>Humanwell\u2019s trial design follows the regulatory framework for analgesic drugs in China, with primary endpoints including pain intensity scores (VAS) and opioid\u2011free analgesic consumption over 48\u202fhrs post\u2011operation.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-acute-pain-therapeutics-in-china\">Market Context \u2013 Acute\u2011Pain Therapeutics in China<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Competitive Landscape<\/strong>:<\/li>\n\n\n\n<li>1 company has progressed to Phase\u202f2\/3 for a drug targeting the same mechanism.<\/li>\n\n\n\n<li>4 companies remain in Phase\u202f2 of similar acute\u2011pain agents.<\/li>\n\n\n\n<li>2 companies are at Phase\u202f1.<\/li>\n\n\n\n<li><strong>Regulatory Opportunity<\/strong>:<\/li>\n\n\n\n<li>The Chinese National Medical Products Administration (NMPA) encourages development of novel, non\u2011opioid analgesics with improved safety profiles.<\/li>\n\n\n\n<li>Successful Phase\u202f2 data could accelerate a 30\u2011day Phase\u202f3 launch, potentially capturing >\u202f$500\u202fM of the domestic post\u2011operative analgesia market.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-humanwell-s-position\">Humanwell\u2019s Position<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Innovation<\/strong>: HW231019 utilizes a <em>selective receptor subtype modulation<\/em> strategy that has shown promising pre\u2011clinical safety data.<\/li>\n\n\n\n<li><strong>Portfolio Synergy<\/strong>: The company\u2019s existing pipeline in <em>pain management<\/em> and <em>hospital\u2011based therapies<\/em> positions it well for rapid scale\u2011up.<\/li>\n\n\n\n<li><strong>Commercial Outlook<\/strong>: If Phase\u202f2 proves positive, Humanwell plans to pursue NMPA approval and a parallel U.S. filing to align with a global commercialization strategy.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-forward-looking-statements\">Forward\u2011Looking Statements<\/h2>\n\n\n\n<p>This brief contains forward\u2011looking statements concerning Humanwell\u2019s clinical program, regulatory prospects, and commercial potential. Actual results may differ materially due to clinical, regulatory, and market risks.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/600079_20251113_1YUA.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600079_20251113_1YUA.\"><\/object><a id=\"wp-block-file--media-ec1b3311-7380-4063-a791-306163dd0d25\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/600079_20251113_1YUA.pdf\">600079_20251113_1YUA<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/600079_20251113_1YUA.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-ec1b3311-7380-4063-a791-306163dd0d25\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced that it has begun a Phase\u202f2 clinical&#8230;<\/p>\n","protected":false},"author":1,"featured_media":47704,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,266,1098],"class_list":["post-47699","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-humanwell-healthcare","tag-sha-600079"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Humanwell Initiates Phase\u202f2 Trial of HW231019 Tablets for Post\u2011Abdominal Surgery Analgesia - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced that it has begun a Phase\u202f2 clinical trial of its novel acute\u2011pain therapy, HW231019 tablets, aimed at reducing post\u2011operative pain after abdominal surgery.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=47699\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Humanwell Initiates Phase\u202f2 Trial of HW231019 Tablets for Post\u2011Abdominal Surgery Analgesia\" \/>\n<meta property=\"og:description\" content=\"Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced that it has begun a Phase\u202f2 clinical trial of its novel acute\u2011pain therapy, HW231019 tablets, aimed at reducing post\u2011operative pain after abdominal surgery.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=47699\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-13T14:18:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-13T14:18:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1307.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47699#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47699\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Humanwell Initiates Phase\u202f2 Trial of HW231019 Tablets for Post\u2011Abdominal Surgery Analgesia\",\"datePublished\":\"2025-11-13T14:18:37+00:00\",\"dateModified\":\"2025-11-13T14:18:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47699\"},\"wordCount\":287,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47699#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1307.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Humanwell Healthcare\",\"SHA: 600079\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=47699#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47699\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=47699\",\"name\":\"Humanwell Initiates Phase\u202f2 Trial of HW231019 Tablets for Post\u2011Abdominal Surgery Analgesia - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47699#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47699#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1307.webp\",\"datePublished\":\"2025-11-13T14:18:37+00:00\",\"dateModified\":\"2025-11-13T14:18:39+00:00\",\"description\":\"Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced that it has begun a Phase\u202f2 clinical trial of its novel acute\u2011pain therapy, HW231019 tablets, aimed at reducing post\u2011operative pain after abdominal surgery.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47699#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=47699\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47699#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1307.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1307.webp\",\"width\":1080,\"height\":608,\"caption\":\"Humanwell Initiates Phase\u202f2 Trial of HW231019 Tablets for Post\u2011Abdominal Surgery Analgesia\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47699#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Humanwell Initiates Phase\u202f2 Trial of HW231019 Tablets for Post\u2011Abdominal Surgery Analgesia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Humanwell Initiates Phase\u202f2 Trial of HW231019 Tablets for Post\u2011Abdominal Surgery Analgesia - Insight, China&#039;s Pharmaceutical Industry","description":"Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced that it has begun a Phase\u202f2 clinical trial of its novel acute\u2011pain therapy, HW231019 tablets, aimed at reducing post\u2011operative pain after abdominal surgery.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=47699","og_locale":"en_US","og_type":"article","og_title":"Humanwell Initiates Phase\u202f2 Trial of HW231019 Tablets for Post\u2011Abdominal Surgery Analgesia","og_description":"Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced that it has begun a Phase\u202f2 clinical trial of its novel acute\u2011pain therapy, HW231019 tablets, aimed at reducing post\u2011operative pain after abdominal surgery.","og_url":"https:\/\/flcube.com\/?p=47699","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-13T14:18:37+00:00","article_modified_time":"2025-11-13T14:18:39+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1307.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=47699#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=47699"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Humanwell Initiates Phase\u202f2 Trial of HW231019 Tablets for Post\u2011Abdominal Surgery Analgesia","datePublished":"2025-11-13T14:18:37+00:00","dateModified":"2025-11-13T14:18:39+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=47699"},"wordCount":287,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=47699#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1307.webp","keywords":["Clinical trial approval \/ initiation","Humanwell Healthcare","SHA: 600079"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=47699#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=47699","url":"https:\/\/flcube.com\/?p=47699","name":"Humanwell Initiates Phase\u202f2 Trial of HW231019 Tablets for Post\u2011Abdominal Surgery Analgesia - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=47699#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=47699#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1307.webp","datePublished":"2025-11-13T14:18:37+00:00","dateModified":"2025-11-13T14:18:39+00:00","description":"Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced that it has begun a Phase\u202f2 clinical trial of its novel acute\u2011pain therapy, HW231019 tablets, aimed at reducing post\u2011operative pain after abdominal surgery.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=47699#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=47699"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=47699#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1307.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1307.webp","width":1080,"height":608,"caption":"Humanwell Initiates Phase\u202f2 Trial of HW231019 Tablets for Post\u2011Abdominal Surgery Analgesia"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=47699#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Humanwell Initiates Phase\u202f2 Trial of HW231019 Tablets for Post\u2011Abdominal Surgery Analgesia"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1307.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/47699","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=47699"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/47699\/revisions"}],"predecessor-version":[{"id":47706,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/47699\/revisions\/47706"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/47704"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=47699"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=47699"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=47699"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}